SNX-25a, a novel Hsp90 inhibitor, inhibited human cancer growth more potently than 17-AAG

Biochemical and Biophysical Research Communications

Volumn 450, Issue 1, 2014, Pages 73-80

  Wang, Shaoxiang ^a,b   Wang, Xiao ^b   Du, Zhan ^c   Liu, Yuting ^a   Huang, Dane ^a   Zheng, Kai ^b   Liu, Kaisheng ^a   Zhang, Yi ^a   Zhong, Xueyun ^a   Wang, Yifei ^a  

^a JINAN UNIVERSITY   (China)

^b Shenzhen University School of Medicine   (China)

^c NANCHANG UNIVERSITY   (China)

Author keywords

17 AAG; Apoptosis; Cell growth; Client proteins; Hsp90; SNX 25a

Indexed keywords

HEAT SHOCK PROTEIN 90 INHIBITOR; SNX 25A; TANESPIMYCIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER CELL LINE; CANCER INHIBITION; CELL CYCLE G2 PHASE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENCY; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOLECULAR DOCKING; PRIORITY JOURNAL;

17-AAG; APOPTOSIS; CELL GROWTH; CLIENT PROTEINS; HSP90; SNX-25A;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZOQUINONES; CELL LINE, TUMOR; CELL PROLIFERATION; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; NEOPLASMS, EXPERIMENTAL; TREATMENT OUTCOME;

EID: 84904753193     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2014.05.076     Document Type: Article

References (35)

1. L.H. Pearl, and C. Prodromou Structure and mechanism of the Hsp90 molecular chaperone machinery Annu. Rev. Biochem. 75 2006 271 294
2. J. Trepel, M. Mollapour, G. Giaccone, and L. Neckers Targeting the dynamic HSP90 complex in cancer Nat. Rev. Cancer 10 2010 537 549
3. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
4. D. Mahalingam, R. Swords, J.S. Carew, S.T. Nawrocki, K. Bhalla, and F.J. Giles Targeting HSP90 for cancer therapy Br. J. Cancer 100 2009 1523 1529
5. J.P. Grenert, W.P. Sullivan, P. Fadden, T.A. Haystead, J. Clark, E. Mimnaugh, H. Krutzsch, H.J. Ochel, T.W. Schulte, E. Sausville, L.M. Neckers, and D.O. Toft The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation J. Biol. Chem. 272 1997 23843 23850
6. S.Z. Usmani, R. Bona, and Z. Li 17 AAG for HSP90 inhibition in cancer - from bench to bedside Curr. Mol. Med. 9 2009 654 664
7. J.R. Porter, C.C. Fritz, and K.M. Depew Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy Curr. Opin. Chem. Biol. 14 2010 412 420
8. R.L. Cysyk, R.J. Parker, J.J. Barchi Jr., P.S. Steeg, N.R. Hartman, and J.M. Strong Reaction of geldanamycin and C17-substituted analogues with glutathione: product identifications and pharmacological implications Chem. Res. Toxicol. 19 2006 376 381
9. K.H. Huang, J.M. Veal, R.P. Fadden, J.W. Rice, J. Eaves, J.P. Strachan, A.F. Barabasz, B.E. Foley, T.E. Barta, W. Ma, M.A. Silinski, M. Hu, J.M. Partridge, A. Scott, L.G. DuBois, T. Freed, P.M. Steed, A.J. Ommen, E.D. Smith, P.F. Hughes, A.R. Woodward, G.J. Hanson, W.S. McCall, C.J. Markworth, L. Hinkley, M. Jenks, L. Geng, M. Lewis, J. Otto, B. Pronk, K. Verleysen, and S.E. Hall Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents J. Med. Chem. 52 2009 4288 4305
10. D.C. Chinn, W.S. Holland, J.M. Yoon, T. Zwerdling, and P.C. Mack Anti-tumor activity of the HSP90 inhibitor SNX-2112 in pediatric cancer cell lines Pediatr. Blood Cancer 58 2012 885 890
11. M. Taipale, D.F. Jarosz, and S. Lindquist HSP90 at the hub of protein homeostasis: emerging mechanistic insights Nat. Rev. Mol. Cell Biol. 11 2010 515 528
12. T. Bachleitner-Hofmann, M.Y. Sun, C.T. Chen, D. Liska, Z. Zeng, A. Viale, A.B. Olshen, M. Mittlboeck, J.G. Christensen, N. Rosen, D.B. Solit, and M.R. Weiser Antitumor activity of SNX-2112, a synthetic heat shock protein-90 inhibitor, in MET-amplified tumor cells with or without resistance to selective MET inhibition Clin. Cancer Res. 17 2011 122 133
13. H.A. Crissman, and J.A. Steinkamp Rapid, simultaneous measurement of DNA, protein, and cell volume in single cells from large mammalian cell populations J. Cell Biol. 59 1973 766 771
14. A. Rajan, R.J. Kelly, J.B. Trepel, Y.S. Kim, S.V. Alarcon, S. Kummar, M. Gutierrez, S. Crandon, W.M. Zein, L. Jain, B. Mannargudi, W.D. Figg, B.E. Houk, M. Shnaidman, N. Brega, and G. Giaccone A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas Clin. Cancer Res. 17 2011 6831 6839
15. Y.H. Lee, N.H. Lee, G. Bhattarai, J.S. Yun, T.I. Kim, E.C. Jhee, and H.K. Yi PPARgamma inhibits inflammatory reaction in oxidative stress induced human diploid fibloblast Cell Biochem. Funct. 28 2010 490 496
16. W.J. Bettger, S.T. Boyce, B.J. Walthall, and R.G. Ham Rapid clonal growth and serial passage of human diploid fibroblasts in a lipid-enriched synthetic medium supplemented with epidermal growth factor, insulin, and dexamethasone Proc. Natl. Acad. Sci. U.S.A. 78 1981 5588 5592
17. D. Huang, Q. Gu, H. Ge, J. Ye, N.K. Salam, A. Hagler, H. Chen, and J. Xu On the value of homology models for virtual screening: discovering hCXCR3 antagonists by pharmacophore-based and structure-based approaches J. Chem. Inf. Model. 52 2012 1356 1366
18. T. Kawano, T. Kobayakawa, Y. Fukuma, H. Yukitake, Y. Kikuchi, M. Shoji, K. Nakayama, A. Mizuno, T. Takagi, and T.K. Nemoto A comprehensive study on the immunological reactivity of the Hsp90 molecular chaperone J. Biochem. 136 2004 711 722
19. A.S. Sreedhar, E. Kalmar, P. Csermely, and Y.F. Shen Hsp90 isoforms: functions, expression and clinical importance FEBS Lett. 562 2004 11 15
20. D.S. Hong, U. Banerji, B. Tavana, G.C. George, J. Aaron, and R. Kurzrock Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions Cancer Treat. Rev. 39 2013 375 387
21. M. Marzec, D. Eletto, and Y. Argon GRP94: an HSP90-like protein specialized for protein folding and quality control in the endoplasmic reticulum Biochim. Biophys. Acta 2012 1823 774 787
22. D.S. Matassa, M.R. Amoroso, F. Maddalena, M. Landriscina, and F. Esposito New insights into TRAP1 pathway Am. J. Cancer Res. 2 2012 235 248
23. A. Kamal, L. Thao, J. Sensintaffar, L. Zhang, M.F. Boehm, L.C. Fritz, and F.J. Burrows A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors Nature 425 2003 407 410
24. M. Vilenchik, D. Solit, A. Basso, H. Huezo, B. Lucas, H. He, N. Rosen, C. Spampinato, P. Modrich, and G. Chiosis Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90 Chem. Biol. 11 2004 787 797
25. Y. Miyata Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents Curr. Pharm. Des. 11 2005 1131 1138
26. L. Jin, C.L. Xiao, C.H. Lu, M. Xia, G.W. Xing, S. Xiong, Q.Y. Liu, H. Liu, Y.C. Li, F. Ge, Q.D. Wang, Q.Y. He, and Y.F. Wang Transcriptomic and proteomic approach to studying SNX-2112-induced K562 cells apoptosis and anti-leukemia activity in K562-NOD/SCID mice FEBS Lett. 583 2009 1859 1866
27. M. Karin Nuclear factor-kappaB in cancer development and progression Nature 441 2006 431 436
28. A. Israel The IKK complex, a central regulator of NF-kappaB activation Cold Spring Harb. Perspect. Biol. 2 2010 a000158
29. T. Holmes, T.A. O'Brien, R. Knight, R. Lindeman, S. Shen, E. Song, G. Symonds, and A. Dolnikov Glycogen synthase kinase-3beta inhibition preserves hematopoietic stem cell activity and inhibits leukemic cell growth Stem Cells 26 2008 1288 1297
30. Z. Wang, K.S. Smith, M. Murphy, O. Piloto, T.C. Somervaille, and M.L. Cleary Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy Nature 455 2008 1205 1209
31. C. Cavelier, C. Didier, N. Prade, V. Mansat-De, V. Mansat-De Mas, S. Manenti, C. Recher, C. Demur, and B. Ducommun Constitutive activation of the DNA damage signaling pathway in acute myeloid leukemia with complex karyotype: potential importance for checkpoint targeting therapy Cancer Res. 69 2009 8652 8661
32. J.H. Lee, M.L. Choy, L. Ngo, G. Venta-Perez, and P.A. Marks Role of checkpoint kinase 1 (Chk1) in the mechanisms of resistance to histone deacetylase inhibitors Proc. Natl. Acad. Sci. U.S.A. 108 2011 19629 19634
33. L.S. Steelman, R.A. Franklin, S.L. Abrams, W. Chappell, C.R. Kempf, J. Basecke, F. Stivala, M. Donia, P. Fagone, F. Nicoletti, M. Libra, P. Ruvolo, V. Ruvolo, C. Evangelisti, A.M. Martelli, and J.A. McCubrey Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy Leukemia 25 2011 1080 1094
34. P. Sancho, E. Galeano, M.C. Estan, I. Ganan-Gomez, and C. Boyano-Adanez Mdel, A.I. Garcia-Perez, Raf/MEK/ERK signaling inhibition enhances the ability of dequalinium to induce apoptosis in the human leukemic cell line K562 Exp. Biol. Med. (Maywood) 237 2012 933 942
35. J.M. Davis, P.M. Navolanic, C.R. Weinstein-Oppenheimer, L.S. Steelman, W. Hu, M. Konopleva, M.V. Blagosklonny, and J.A. McCubrey Raf-1 and Bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistance Clin. Cancer Res. 9 2003 1161 1170